MEDIUM confidence: 100% data completeness, but the composite (46) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Net insider -$10.7M over 180 days (0 open-market buys, 5 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $56.2B— | $58.1B+3.3% | $54.3B-6.4% | $56.3B+3.7% | $61.2B+8.6% |
| EPS (dil.) | $6.45— | $6.63+2.8% | $2.72-59.0% | $2.39-12.1% | $2.37-0.8% |
| Free Cash Flow | $22.0B— | $24.2B+10.3% | $22.1B-9.0% | $17.8B-19.2% | $17.8B-0.1% |
| Gross Margin | 69.0% | 70.0%+1.0pp | 62.4%-7.6pp | 70.0%+7.6pp | 70.2%+0.2pp |
| Operating Margin | 31.9% | 31.2%-0.7pp | 23.5%-7.7pp | 16.2%-7.3pp | 32.8%+16.6pp |
| Net Margin | 20.5% | 20.4%-0.2pp | 9.0%-11.4pp | 7.6%-1.4pp | 6.9%-0.7pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Avg target $281 (last qtr, 17 analysts) → $288 (last mo, 7) (+2.4%).
Buy-rated share 73% → 77% over ~3 months (+5pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jul 2026 | $3.61 | $3.65 | +1.1% |
| Apr 2026 | $2.59 | $2.65 | +2.3% |
| Feb 2026 | $2.65 | $2.71 | +2.3% |
| Oct 2025 | $1.77 | $1.86 | +5.1% |
| Jul 2025 | $2.88 | $2.97 | +3.1% |
| Apr 2025 | $2.38 | $2.46 | +3.4% |
| Jan 2025 | $2.98 | $2.16 | -27.5% |
| Oct 2024 | $2.92 | $3.00 | +2.7% |
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 5.8%/yr (revenue basis).
Base free cash flow $19.2B (avg FY2023–FY2025; latest year $17.8B) · equity value $447.4B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 46 for AbbVie indicates a neutral outlook, with the stock's short-term score exceeding its long-term score by 6 points. The stock scores high on momentum, driven by a 27.1% return over the past year and a bullish 50-day versus 200-day moving average trend. However, it trades at a premium, with a P/E of 71.3, which weighs down its value score. Profitability metrics are mixed, with a strong gross margin but a negative ROE, contributing to the stock's overall middling QScore.